Principal Financial Group
DFTX icon

Principal Financial Group’s Definium Therapeutics DFTX Stock Holding History

Principal Financial Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$550K Buy
14,451
+4,499
+45% +$190K ﹤0.01% 2001
2026
Q2 		$468K Buy
+9,952
New +$246K ﹤0.01% 2008
2022
Q2 		– Sell
-3,899
Closed -$65K – 2600
2022
Q1 		$65K Sell
3,899
-47
-1% -$815 ﹤0.01% 2473
2021
Q4 		$82K Sell
3,946
-921
-19% -$29.4K ﹤0.01% 2455
2021
Q3 		$170K Buy
4,867
+1,434
+42% +$62K ﹤0.01% 2451
2021
Q2 		$178K Buy
+3,433
New +$180K ﹤0.01% 2485

Other funds holding DFTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Principal Financial Group's DFTX Position: Q3 2026 in Review

Principal Financial Group increased its Definium Therapeutics (DFTX) stake by 45% in Q3 2026, buying an estimated $190K and bringing the position to 14,451 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #2001.

Principal Financial Group first reported a position in DFTX in Q2 2021 and has held it in 6 quarters since. 159 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Principal Financial Group held 14,451 shares of Definium Therapeutics worth $550K as of Q3 2026.
  • Principal Financial Group bought 4,499 Definium Therapeutics shares in Q3 2026, an estimated $190K.
  • Definium Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q3 2026, its #2001 holding.
  • Principal Financial Group first reported a position in Definium Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Principal Financial Group's 13F filing for Q3 2026, filed 2 Nov 2026.